Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

Kazunari Tanaka; Kunihiko Tsuji; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Toru Ishikawa; Kazuto Tajiri; Hironori Tanaka; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Yoshihide Ueda; Hidekatsu Kuroda; Yutaka Yata; Hiroki Nishikawa; Michitaka Imai; Takashi Aoki; Hironori Ochi; Jumpei Okamura; Hideyuki Tamai; Shinichiro Nakamura; Yoshiko Nakamura; Osamu Yoshida; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Fujimasa Tada; Hideko Ohama; Yuichi Koshiyama; Yuki Kanayama; Hidenao Noritake; Shohei Komatsu; Takumi Fukumoto; Takanori Matsuura; Soo Ki Kim; Hirayuki Enomoto; Kosuke Matsui; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi Kumada

doi:10.1111/hepr.70178

Shared by

Masatoshi Kudo

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

Article 2026 en

Authors

KT
Kazunari Tanaka
KT
Kunihiko Tsuji
AH
Atsushi Hiraoka

Abstract

1 min read

In metastatic HCC treated with atezolizumab plus bevacizumab, intrahepatic tumor burden was associated with overall survival and may be useful for risk stratification and treatment optimization.

Related publications

Article2024

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma☆

Parissa Tabrizian, Rebecca Marino, Sherrie Bhoori, Marcus Zeitlhoefler, Neil Mehta, Vanessa Banz, Salvatore Gruttadauria, Massimo Iavarone, Chiara Mazzarelli, Nicolò Simonotti, Francis Y. Yao, Vincenzo Mazzaferro, Josep M. Llovet

JHEP Reports

Article2023

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.

Margherita Rimini, Andrea Casadei‐Gardini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Mario Scartozzi, Valentina Burgio, Stefano Cascinu, Alessandro Cucchetti

Dataset

Supplementary Material for: Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

M. Rimini, M. Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, F. Finkelmeier, Lim H.Y., J. PresaRamos, Gianluca Masi, Yoo C., S. Lonardi, Bernardo Stefanini, Takashi Kumada, Naomi Sakamoto, Hideki Iwamoto, Tomoko Aoki, Chon H.J., Vera Himmelsbach, Melania Montes, Caterina Vivaldi, ,

Article2021

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy

Masatoshi Kudo

Article2022

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Linda Y. Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Jaekyung Cheon, Naoshi Nishida, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Yi‐Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein,

Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab

Abstract

Discussion(0)

Related publications

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma☆

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.

Supplementary Material for: Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab